Cost-Effectiveness Analysis of Lenvatinib plus Pembrolizumab or Everolimus as First-Line Treatment for Advanced Renal Cell Carcinoma
2024 · Clinical Genitourinary Cancer · 3 citations
https://doi.org/10.1016/j.clgc.2024.102264
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
9
Papers
60
Citations
4
h-index
2
i10-index
Huanrui Zheng is an academic researcher from Fujian Medical University. The author has contributed to research in topics: Pancreatic and Hepatic Oncology Research & Pulmonary Hypertension Research and Treatments & Economic and Financial Impacts of Cancer. The author has an h-index of 4, co-authored 8 publications.
Click to start Chat